Pharmaceutical Technology

JUNE 6, 2023

The global pharma industry experienced an 11% rise in social media posts on regenerative medicine in Q1 2023 compared with the previous quarter, with the highest share accounted for Pfizer, according to GlobalData’s analysis of social media posts. Buy the report here.

Medicine 100

Medicine Drugs Research 100

Pharmaceutical Technology

JULY 19, 2022

All aspects of environmental, social, and governance (ESG) are important, and in the healthcare industry, companies must excel across all three. Listed below are the impact of ESG on healthcare, as identified by GlobalData. The post ESG Top Trends: Healthcare ESG Impact appeared first on Pharmaceutical Technology.

Medicine 162

Medicine Manufacturing Vaccination Vaccine 162

Pharmaceutical Technology

DECEMBER 12, 2022

The successful implementation of these contracts is necessary to ensure that a newly approved drug or an investigational therapy that is ready to advance to the next pivotal stage of clinical evaluation is manufactured in a timely manner. Previously, Iomab-B received an EMA orphan drug designation for patients with this condition.

Manufacturing 147

Manufacturing Drugs Packaging Packaging 147

Pharmaceutical Technology

NOVEMBER 22, 2022

Drug shortages continue to affect medical care in healthcare systems, and experts tell us that supply bottlenecks for cardiovascular drugs are particularly concerning. All this, and the latest pharma industry news , comment, data, and analysis from GlobalData.

Regulation 233

Regulation Drugs 233

Pharmaceutical Technology

FEBRUARY 23, 2023

In the last three years alone, there have been over 633,000 patents filed and granted in the pharmaceutical industry, according to GlobalData’s report on Artificial Intelligence in Pharmaceuticals: In-silico drug discovery. Adimab and Xencor are the other key patent filers of in-silico drug discovery.

Drugs 189

Drugs DNA In-Vivo In-Vitro 189

Pharmaceutical Technology

MARCH 2, 2023

According to GlobalData, Phase I drugs for Relapsed Acute Myeloid Leukemia have a 71% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how QN-023a’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks.

Gene Editing 100

Gene Editing Genetic Engineering Engineer Clinical Trials 100

Pharmaceutical Technology

MARCH 2, 2023

According to GlobalData, Phase I drugs for B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic Leukaemia) have a 90% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. Hangzhou Qihan Biotechnology overview Hangzhou Qihan Biotechnology is a healthcare company. Buy the report here.

Gene Editing 100

Gene Editing Clinical Trials Clinical Trials Genetics 100

Pharmaceutical Technology

FEBRUARY 14, 2023

In the last three years alone, there have been over 633,000 patents filed and granted in the pharmaceutical industry, according to GlobalData’s report on Key innovation: Leading companies in nanoparticles for drug delivery. Bristol-Myers Squibb is the leading patent filer in nanoparticles for drug delivery.

Drug Delivery 147

Drug Delivery Drugs Drug Delivery Systems FDA Approval 147

Pharmaceutical Technology

FEBRUARY 28, 2023

According to GlobalData, Phase I drugs for Malignant Mesothelioma have a 77% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how KFA-115’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks.

Generic Pharmaceutical 100

Generic Pharmaceutical Dermatology Clinical Trials Clinical Trials 100

Pharmaceutical Technology

JANUARY 2, 2023

The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next. It also offers animal healthcare products for Swine, Ruminant, Poultry, Horses, Pets etc.

Drugs 100

Drugs Production Manufacturing Development 100

Pharmaceutical Technology

FEBRUARY 20, 2023

According to GlobalData, Phase II drugs for Systemic Sclerosis (Scleroderma) have a 24% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how BI-685509’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks.

Production 100

Production Manufacturing Clinical Trials Clinical Trials 100

Pharmaceutical Technology

JULY 21, 2022

As part of ESG (Environmental, Social, and Governance), the social good delivered by robust healthcare systems are at the core of healthy populations. The Covid-19 pandemic has demonstrated how vital patient access to quality and affordable healthcare is for patients all over the world. Drug pricing and gouging.

Pharma Companies 130

Pharma Companies Clinical Trials Clinical Trials Drugs 130

Pharmaceutical Technology

JUNE 5, 2023

According to GlobalData, Phase I drugs for Hypopharyngeal Cancer does not have sufficient historical data to build an indication benchmark PTSR for Phase I. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the BI-765063 LoA Report. Buy the report here.

Production 100

Production Manufacturing Drugs Clinical Trials 100

Pharmaceutical Technology

FEBRUARY 28, 2023

According to GlobalData, Phase III drugs for Paroxysmal Nocturnal Hemoglobinuria have a 60% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Generic Pharmaceutical 100

Generic Pharmaceutical Dermatology Clinical Trials Clinical Trials 100

Pharmaceutical Technology

FEBRUARY 28, 2023

According to GlobalData, Phase III drugs for Glomerulonephritis have a 67% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval. Buy the report here.

Generic Pharmaceutical 100

Generic Pharmaceutical Dermatology Clinical Trials Clinical Trials 100

Pharmaceutical Technology

MARCH 1, 2023

According to GlobalData, Phase I drugs for Neuroendocrine Tumors have a 74% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Nedisertib’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks.

Gene Editing 100

Gene Editing DNA Cosmetics Life Science 100

Pharmaceutical Technology

MARCH 1, 2023

According to GlobalData, Phase I drugs for Head And Neck Cancer Squamous Cell Carcinoma have an 80% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Gene Editing 100

Gene Editing DNA Cosmetics Life Science 100

Pharmaceutical Technology

DECEMBER 7, 2022

On 29 November, the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) warned of some new and potentially serious eye-related side effects associated with Dupixent, an interleukin (IL)-4/13 inhibitor drug used in the treatment of numerous allergic indications such as atopic dermatitis, asthma and nasal polyps.

Production 162

Production Regulation Clinical Trials Clinical Trials 162

Pharmaceutical Technology

JULY 28, 2022

Many of the mainstay drugs for the treatment of moderate to severely active UC, such as anti-tumour necrosis factor (anti-TNF) agents like infliximab, target inflammatory mediators that are dysregulated in this condition. GlobalData expects regulatory approval of mirikizumab for UC in the US and European Union (EU) next year.

Trials 246

Trials Marketing RNA Development 246

Pharmaceutical Technology

MARCH 22, 2023

Healthcare providers are under pressure to address the growing issue of substance use disorders. According to GlobalData’s Medical Device Pipeline Analytics, there are 61 products in development for treating substance abuse disorders classed as healthcare IT.

FDA Approval 130

FDA Approval Production Compliance Clinical Trials 130

Pharmaceutical Technology

JULY 14, 2022

Regulatory decisions have a ripple effect, first affecting the pharma sponsors, and then the companies tasked to manufacture the drug. Pharmaceutical Technology looks at drugs and biologics with recent regulatory verdicts that will likely impact manufacturing volumes. Covid-19 vaccines stay in the spotlight.

Manufacturing 130

Manufacturing Drugs Vaccination Vaccine 130

Pharmaceutical Technology

JUNE 5, 2023

According to GlobalData, Phase II drugs for Pancreatic Cancer have a 25% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Pralsetinib’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks.

In-Vitro 100

In-Vitro Drugs Clinical Trials Clinical Trials 100

Pharmaceutical Technology

FEBRUARY 10, 2023

million, according to GlobalData’s Price Intelligence (POLI), making it the most expensive drug in the world. Partly in response to such drugs, risk-sharing agreements (RSAs) have increased in popularity and aim to mitigate the risks of including high-cost drugs on reimbursement lists and healthcare plans.

Gene Therapy 263

Gene Therapy Marketing Gene Drugs 263

Pharmaceutical Technology

APRIL 13, 2023

Following the increased use of telemedicine during the Covid-19 pandemic, the potential of digital technologies in communication, data collection, and analysis has become increasingly realised by patients, healthcare systems, and clinical trial sponsors.

Clinical Trials 130

Clinical Trials Clinical Trials Trials Dermatology 130

Pharmaceutical Technology

FEBRUARY 24, 2023

According to Globaldata, it is involved in 10 clinical trials, of which 4 were completed, 5 are ongoing, and 1 is planned. GlobalData uses proprietary data and analytics to provide a complete picture of Retatrutide’s valuation in its risk-adjusted NPV model (rNPV). The drug candidate is administered through subcutaneous route.

Sales 113

Sales Production Clinical Trials Clinical Trials 113

Pharmaceutical Technology

JULY 14, 2022

The commercial investment required to research and develop an innovative drug, prove its safety and efficacy, and bring it to market is staggering. Most famously, the US passed its Orphan Drug Act in 1983, providing innovators with financial motivation to develop orphan drugs and meet the needs of these forgotten patients.

Drugs 147

Drugs Medicine Marketing Development 147

Pharmaceutical Technology

APRIL 19, 2023

Bayer has announced that it will shift the focus of its drug research away from women’s health to four core therapeutic areas: oncology, cardiovascular, neurology and rare diseases/immunology.

Gene Therapy 130

Gene Therapy Hormones Production Sales 130

Pharmaceutical Technology

JULY 25, 2022

The COVID-19 pandemic triggered significant changes to the way healthcare operates. According to Tom Lenaerts, Head of Global Process Engineering at Datwyler, this transformation will reshape the entire healthcare ecosystem.

Engineer 286

Engineer Packaging Packaging Production 286

World of DTC Marketing

AUGUST 12, 2022

PhRMA is lying to protect its profits, and the lies have reached a new height as the Senate moved to adopt modest drug pricing negotiation measures in the Inflation Reduction Act. Of course, the drug industry warns that any price negotiation will kill innovation. First, let’s clarify how the bill saves taxpayers billions.

Drugs 255

Drugs Research Development Regulation 255

Pharmaceutical Technology

MAY 31, 2023

More than half (54%) of the surveyed healthcare industry professionals indicated that their sentiment towards Brexit had become more negative. A Brexit survey conducted previously by GlobalData in 2021 found that the majority (60%) of the respondents had a more neutral sentiment towards Brexit at that point.

Life Science 55

Life Science Manufacturing Regulation Medicine 55

Pharmaceutical Technology

MARCH 10, 2023

In Lebanon, the battle for access to medicines rages on and is further heightened by dramatic decreases to the healthcare budget last year. GlobalData reviews the key events leading up to these current price trends in Lebanon. Additionally, Lebanon relies on foreign currency for 80% of drugs.

Marketing 130

Marketing Branding Manufacturing Medicine 130

Pharmaceutical Technology

OCTOBER 26, 2022

On October 6, in a GlobalData webinar, experts tried to answer the question ‘ Is Pharma at an ESG turning point?’ , revealing a multitude of diverse strategies for pharmaceutical companies to remain conscious of their global impacts. GlobalData is the parent company of Pharmaceutical Technology. Health disparities today.

Clinical Trials 162

Clinical Trials Clinical Trials Trials Life Science 162

Pharmaceutical Technology

MARCH 31, 2023

The new facility is expected to enable the manufacturing of drug products for Kenya and Africa, and will be able to quickly scale up its production and respond to public health emergencies on the continent and worldwide. The company is also committed to establishing mRNA manufacturing facilities in Australia, Canada, the US and the UK.

Manufacturing 264

Manufacturing Gene Therapy Gene Genetics 264

XTalks

MAY 2, 2024

In 2023, the US Food and Drug Administration (FDA) approved a record-breaking 61 drugs, the most in history. Since January, the FDA has already signed off on more than a dozen novel drugs. The agency is reviewing applications for several highly anticipated drugs for approval in 2024.

Drugs 52

Drugs FDA Approval Sales Vaccination 52

Pharmaceutical Technology

MAY 16, 2023

UniQure is selling a part of its royalty rights to the haemophilia B gene therapy Hemgenix (etranacogene dezaparvovec) to HealthCare Royalty and Sagard Healthcare for a gross purchase price of up to $400 million dollars. HealthCare Royalty is a royalty acquisition company. HealthCare Royalty is a royalty acquisition company.

Gene Therapy 130

Gene Therapy Gene Sales Development 130

Pharmaceutical Technology

APRIL 19, 2023

Telehealth is on the rise , with its market expected to be worth $3.8bn by 2030, according to GlobalData. Telehealth is especially important for improving healthcare accessibility in rural regions. Pharmacy chains have become the backbone for providing infrastructure to roll out telehealth services.

Dermatology 130

Dermatology Pharmacy Branding Marketing 130

Pharmaceutical Technology

JULY 7, 2022

There is a lot of excitement that we could be at the start of a new era for the biopharmaceutical industry, with the hope of delivering revolutionary healthcare for previously unaddressed diseases finally becoming a reality. A new frontier in cancer research. Securing the supply chain. The industry is moving at an unprecedented speed.

Gene Therapy 245

Gene Therapy Gene Medicine Genetics 245